These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 25738213)

  • 21. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Add-on therapies to metformin for type 2 diabetes.
    Shomali M
    Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
    Hermansen K; Mortensen LS
    Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidiabetic therapy effects on bone metabolism and fracture risk.
    Montagnani A; Gonnelli S
    Diabetes Obes Metab; 2013 Sep; 15(9):784-91. PubMed ID: 23368527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
    Wolverton D; Blair MM
    Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral combination therapy in primary care.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes.
    Zhao Q; Marcy TR
    Consult Pharm; 2013 Aug; 28(8):515-8. PubMed ID: 23906896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone metabolism in type 2 diabetes and role of thiazolidinediones.
    Vestergaard P
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):125-31. PubMed ID: 19300092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fracture Risk Assessment in Patients With Diabetes Mellitus.
    Poiana C; Capatina C
    J Clin Densitom; 2017; 20(3):432-443. PubMed ID: 28716499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
    Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
    Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
    Dankner R; Roth J
    Diabet Med; 2020 Feb; 37(2):194-202. PubMed ID: 31769894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.